Finerenone
Authors:
Jan Vachek; Vladimír Tesař
Authors place of work:
Klinika nefrologie 1. LF UK a VFN v Praze
Published in the journal:
Vnitř Lék 2023; 69(E-3): 20-23
Category:
doi:
https://doi.org/10.36290/vnl.2023.037
Summary
In developed countries, diabetes mellitus (DM) is one of the main causes of end stage renal disease (ESRD). In addition, the development of chronic kidney disease (CKD) further increases the already significantly increased cardiovascular (CV) risk in patients with diabetes. Both albuminuria and impaired renal function predict CV disease-related morbidity. The multifactorial pathogenesis of DM-related CKD involves structural, physiological, hemodynamic, and inflammatory processes. Instead of a so-called glucocentric approach, current evidence suggests that a multimodal, interdisciplinary treatment approach is needed to also prevent further progression of CKD and reduce the risk of cardiovascular events. Combined antihypertensive, antihyperglycemic and hypolipidemic therapy is the basis of a comprehensive approach to prevent the progression of diabetic kidney disease. According to recent evidence, adjunctive therapy with the non-steroidal mineralocorticoid receptor antagonist (MRA) finerenone - in addition to the use of an ACE (angiotensin converting enzyme) or AT1 (angiotensin II receptor subtype 1) blocker and an SGLT2 (sodium-glucose cotransporter-2) inhibitor - represents an effective therapeutic tool to improve nephroprotection in CKD. The aim of this review is to provide brief information on this promising pharmacotherapeutic approach to the treatment of diabetic kidney disease.
Keywords:
chronic kidney disease (CKD) – finerenone – diabetes mellitus (DM) – mineralocorticoid receptor antagonists – spironolactone
Zdroje
1. Shlipak MG, Tummalapalli SL, Boulware LE, et al. Conference Participants. The case for early identification and intervention of chronic kidney disease: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. Kidney Int. 2021 Jan;99(1):34-47. doi: 10.1016/j.kint.2020. 10. 012. Epub 2020 Oct 27. PMID: 33127436.
2. Sagoo MK, Gnudi L. Diabetic Nephropathy: An Overview. Methods Mol Biol. 2020;2067:3-7. doi: 10.1007/978-1-4939-9841-8_1. PMID: 31701441.
3. Alder H, Ambühl PM. Diabetische Nephropathie [Managing diabetic kidney disease]. Ther Umsch. 2020 Sep;77(7):333-338. German. doi: 10.1024/0040-5930/a001200. PMID: 32996426.
4. Sourij H, Edlinger R, Prischl FC, et al. Diabetische Nierenerkrankung (Update 2019): Positionspapier der Österreichischen Diabetes Gesellschaft und der Österreichischen Gesellschaft für Nephrologie [Diabetic kidney disease (Update 2019): Position paper of the Austrian Diabetes Association and the Austrian Society for Nephrology]. Wien Klin Wochenschr. 2019 May;131(Suppl 1):151-163. German. doi: 10.1007/s00508-018-1425-x. PMID: 30980144.
5. Watanabe K, Sato E, Mishima E, et al. What’s New in the Molecular Mechanisms of Diabetic Kidney Disease: Recent Advances. Int J Mol Sci. 2022 Dec 29;24(1):570. doi: 10.3390/ijms24010570. PMID: 36614011.
6. Nuffield Department of Population Health Renal Studies Group; SGLT2 inhibitor Meta‑Analysis Cardio‑Renal Trialists‘ Consortium. Impact of diabetes on the effects of sodium glucose co‑transporter-2 inhibitors on kidney outcomes: collaborative meta‑analysis of large placebo‑controlled trials. Lancet. 2022 Nov 19;400(10365):1788-1801. doi: 10.1016/S0140-6736(22)02074-8. Epub 2022 Nov 6. PMID: 36351458; PMCID: PMC7613836.
7. Georgianos PI, Vaios V, Roumeliotis S, et al. Evidence for Cardiorenal Protection with SGLT- 2 Inhibitors and GLP-1 Receptor Agonists in Patients with Diabetic Kidney Disease. J Pers Med. 2022 Feb 6;12(2):223. doi: 10.3390/jpm12020223. PMID: 35207711; PMCID: PMC8874759.
8. Zhou G, Johansson U, Peng XR, et al. An additive effect of eplerenone to ACE inhibitor on slowing the progression of diabetic nephropathy in the db/db mice. Am J Transl Res. 2016 Mar 15;8(3):1339-54. PMID: 27186263; PMCID: PMC4859623.
9. Liu WY, Yu SQ. [Research progress on the cardiorenal protection of non‑steroid mineralocorticoid receptor antagonists in patients with chronic kidney disease]. Sheng Li Xue Bao. 2022 Dec 25;74(6):1023-1030. Chinese. PMID: 36594390.
10. Folkerts K, Millier A, Smela B, et al. Real‑world evidence for steroidal mineralocorticoid receptor antagonists in patients with chronic kidney disease. J Nephrol. 2022 Nov 23. doi: 10.1007/s40620-022-01492-w. Epub ahead of print. PMID: 36422853.
11. Epstein M. Aldosterone and Mineralocorticoid Receptor Signaling as Determinants of Cardiovascular and Renal Injury: From Hans Selye to the Present. Am J Nephrol 2021;52:209-216. doi: 10.1159/000515622
12. Georgianos PI, Agarwal R. The non‑steroidal MRA finerenone in cardiorenal medicine: a state‑of‑the‑art review of the literature. Am J Hypertens. 2022 Nov 4:hpac124. doi: 10.1093/ajh/hpac124. Epub ahead of print. PMID: 36331811.
13. Goulooze SC, Heerspink HJL, van Noort M, et al. Dose‑Exposure‑Response Analysis of the Nonsteroidal Mineralocorticoid Receptor Antagonist Finerenone on UACR and eGFR: An Analysis from FIDELIO‑DKD. Clin Pharmacokinet. 2022 Jul;61(7):1013-1025. doi: 10.1007/s40262-022-01124-3. Epub 2022 May 5. PMID: 35508594; PMCID: PMC9287422.
14. Bakris GL, Agarwal R, Anker SD, Pitt B, Ruilope LM, Rossing P, et al. Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes. N Engl J Med. 2020;383(23):2219-2229. doi: 10.1056/NEJMoa2025845.
15. Bakris GL, Ruilope LM, Anker SD, et al. FIDELIO‑DKD and FIGARO‑DKD Investigators. A prespecified exploratory analysis from FIDELITY examined finerenone use and kidney outcomes in patients with chronic kidney disease and type 2 diabetes. Kidney Int. 2023 Jan;103(1):196-206. doi: 10.1016/j.kint.2022. 08. 040. Epub 2022 Oct 28. PMID: 36367466.
16. A Trial to Learn How Well Finerenone Works and How Safe it is in Adult Participants With Non‑diabetic Chronic Kidney Disease (FIND‑CKD). Available from: https://beta.clinicaltrials. gov/study/NCT05047263
17. Gay HC, Yu J, Persell S, et al. Comparison of Sodium‑Glucose Cotransporter-2 Inhibitor and Glucagon‑Like Peptide-1 Receptor Agonist Prescribing in Patients With Diabetes Mellitus With and Without Cardiovascular Disease.Am J Cardiol. 2023 Feb 15;189:121-130. doi: 10.1016/j.amjcard.2022. 10. 041. Epub 2022 Nov 22.PMID: 3642419
18. Zhang Y, Jiang L, Wang J, Wang T, et al. Network meta‑analysis on the effects of finerenone versus SGLT2 inhibitors and GLP-1 receptor agonists on cardiovascular and renal outcomes in patients with type 2 diabetes mellitus and chronic kidney disease.Cardiovasc Diabetol. 2022 Nov 5;21(1):232. doi: 10.1186/s12933-022-01676-5.
19. Giugliano D, Longo M, Signoriello S, et al. The effect of DPP-4 inhibitors, GLP-1 receptor agonists and SGLT-2 inhibitors on cardiorenal outcomes: a network meta‑analysis of 23 CVOTs.Cardiovasc Diabetol. 2022 Mar 16;21(1):42. doi: 10.1186/s12933-022-01474-z.
20. Schrier RW, Gurevich AK, Cadnapaphornchai MA. Pathogenesis and management of sodium and water retention in cardiac failure and cirrhosis.Semin Nephrol. 2001 Mar;21(2):157-72
21. Zelnick LR, Shlipak MG, Soliman EZ, et al. Prediction of Incident Atrial Fibrillation in Chronic Kidney Disease: The Chronic Renal Insufficiency Cohort Study. Clin J Am Soc Nephrol. 2021 Jul;16(7):1015-1024.
22. Arvid Engström, Viktor Wintzell, Mads Melbye, et al.: Sodium‑Glucose Cotransporter 2 Inhibitor Treatment and Risk of Atrial Fibrillation: Scandinavian Cohort Study. Diabetes Care. 2023 Feb 1;46(2):351-360. doi: 10.2337/dc22-0714.
23. Jennifer B Green, Amy K Mottl, George Bakris, et al. Design of the COmbinatioN effect of FInerenone anD EmpaglifloziN in participants with chronic kidney disease and type 2 diabetes using an UACR Endpoint study (CONFIDENCE)Nephrol Dial Transplant. 2022 Jun 14;gfac198. doi: 10.1093/ndt/gfac198. Online ahead of print.
Štítky
Diabetology Endocrinology Internal medicineČlánok vyšiel v časopise
Internal Medicine
2023 Číslo E-3
Najčítanejšie v tomto čísle
- Finerenone
- Barakat syndrome
- Successful therapy of retroperitoneal fibrosis due to IgG4-related disease with rituximab, cyclophosphamide and glucocorticoids followed by maintenance therapy wit ritutixmab
- Whats new in ESC Guidelines for the management of valvular heart disease?